help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McDonnell, D. P.
Right arrow Articles by Pike, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McDonnell, D. P.
Right arrow Articles by Pike, J. W.

Molecular Endocrinology, Vol 9, 659-669, Copyright © 1995 by Endocrine Society

ARTICLES

Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens

DP McDonnell, DL Clemm, T Hermann, ME Goldman and JW Pike
Department of Pharmacology, Duke University Medical School, Durham, North Carolina 27710, USA.

We have developed a series of in vitro models with which to evaluate the biological activity of estrogen receptor (ER) agonists and antagonists. Using a protease digestion assay we show that the conformational changes induced within ER are distinct for agonists and antagonists. However, this assay is unable to discriminate between pure antagonists like ICI164,384 and partial agonists such as 4-OH tamoxifen or keoxifene. Using a chimeric ER-VP16 construct, we demonstrate that both pure antagonists and partial agonists deliver ER to its DNA target within cells. However, the ability of the DNA-bound receptor to activate transcription in the presence of a given antagonist is dependent on cell and promoter context. These data, suggesting functional differences among ER antagonists, were confirmed by additional experiments demonstrating that their ability to modulate the transcriptional activity of a series of ER mutants is dramatically different. Depending on the cell and promoter context and the particular ER form expressed, 4-OH tamoxifen and the related compound, keoxifene, functioned as partial agonists. Importantly, the transcriptional profiles of these two compounds were dissimilar, suggesting that they are functionally different from each other and from ICI164,384, which does not display agonist activity under any context examined. Our results reveal functional differences between these clinically important antiestrogens and suggest that the distinct biologies manifest by these compounds in vivo relate to their ability to differentially regulate ER function.


This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
N. Levy, D. Tatomer, C. B. Herber, X. Zhao, H. Tang, T. Sargeant, L. J. Ball, J. Summers, T. P. Speed, and D. C. Leitman
Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene
Mol. Endocrinol., February 1, 2008; 22(2): 287 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
T. J. Peterson, S. Karmakar, M. C. Pace, T. Gao, and C. L. Smith
The Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT) Corepressor Is Required for Full Estrogen Receptor {alpha} Transcriptional Activity
Mol. Cell. Biol., September 1, 2007; 27(17): 5933 - 5948.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K. Sasahara, H. Shikimi, S. Haraguchi, H. Sakamoto, S.-i. Honda, N. Harada, and K. Tsutsui
Mode of Action and Functional Significance of Estrogen-Inducing Dendritic Growth, Spinogenesis, and Synaptogenesis in the Developing Purkinje Cell
J. Neurosci., July 11, 2007; 27(28): 7408 - 7417.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Levy, X. Zhao, H. Tang, R. B. Jaffe, T. P. Speed, and D. C. Leitman
Multiple Transcription Factor Elements Collaborate with Estrogen Receptor {alpha} to Activate an Inducible Estrogen Response Element in the NKG2E Gene
Endocrinology, July 1, 2007; 148(7): 3449 - 3458.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Baron, A. Escande, G. Alberola, K. Bystricky, P. Balaguer, and H. Richard-Foy
Estrogen Receptor {alpha} and the Activating Protein-1 Complex Cooperate during Insulin-like Growth Factor-I-induced Transcriptional Activation of the pS2/TFF1 Gene
J. Biol. Chem., April 20, 2007; 282(16): 11732 - 11741.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Physiol. Educ.Home page
M. E. Wierman
Sex steroid effects at target tissues: mechanisms of action
Advan Physiol Educ, March 1, 2007; 31(1): 26 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Dayan, M. Lupien, A. Auger, S. I. Anghel, W. Rocha, S. Croisetiere, J. A. Katzenellenbogen, and S. Mader
Tamoxifen and Raloxifene Differ in Their Functional Interactions with Aspartate 351 of Estrogen Receptor {alpha}
Mol. Pharmacol., August 1, 2006; 70(2): 579 - 588.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B.-S. An, D. M. Selva, G. L. Hammond, A. Rivero-Muller, N. Rahman, and P. C. K. Leung
Steroid Receptor Coactivator-3 Is Required for Progesterone Receptor Trans-activation of Target Genes in Response to Gonadotropin-releasing Hormone Treatment of Pituitary Cells
J. Biol. Chem., July 28, 2006; 281(30): 20817 - 20824.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
V. G. Vogel, J. P. Costantino, D. L. Wickerham, W. M. Cronin, R. S. Cecchini, J. N. Atkins, T. B. Bevers, L. Fehrenbacher, E. R. Pajon Jr, J. L. Wade III, et al.
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
JAMA, June 21, 2006; 295(23): 2727 - 2741.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. Gardner, A. Taylor, G. Wei, A. Calcagni Jr, B. Duncan, and A. Milton
Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women
J. Clin. Pharmacol., January 1, 2006; 46(1): 52 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
J. M. Hall and D. P. McDonnell
Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting
Mol. Interv., December 1, 2005; 5(6): 343 - 357.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
C. J. Larson, D. L. Osburn, K. Schmitz, L. Giampa, S.-M. Mong, K. Marschke, H. M. Seidel, J. Rosen, and A. Negro-Vilar
Peptide Binding Identifies an ER{alpha} Conformation That Generates Selective Activity in Multiple In Vitro Assays
J Biomol Screen, September 1, 2005; 10(6): 590 - 598.
[Abstract] [PDF]

Home page
 EndocrinologyHome page
B. S. Komm, Y. P. Kharode, P. V. N. Bodine, H. A. Harris, C. P. Miller, and C. R. Lyttle
Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Endocrinology, September 1, 2005; 146(9): 3999 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Zhang, A. M. Olland, Y. Zhu, J. Cohen, T. Berrodin, S. Chippari, C. Appavu, S. Li, J. Wilhem, R. Chopra, et al.
Molecular and Pharmacological Properties of a Potent and Selective Novel Nonsteroidal Progesterone Receptor Agonist Tanaproget
J. Biol. Chem., August 5, 2005; 280(31): 28468 - 28475.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Rosen and J. N. Miner
The Search for Safer Glucocorticoid Receptor Ligands
Endocr. Rev., May 1, 2005; 26(3): 452 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. P. McDonnell
The Molecular Pharmacology of Estrogen Receptor Modulators: Implications for the Treatment of Breast Cancer
Clin. Cancer Res., January 15, 2005; 11(2): 871s - 877s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Yamamoto, J. Shibata, K. Yonekura, K. Sato, A. Hashimoto, Y. Aoyagi, K. Wierzba, S. Yano, T. Asao, A. U. Buzdar, et al.
TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor {alpha} and a Partial Agonist on Estrogen Receptor {beta} with Low Uterotrophic Effect
Clin. Cancer Res., January 1, 2005; 11(1): 315 - 322.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Ring and M. Dowsett
Mechanisms of tamoxifen resistance
Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658.
[Abstract] [Full Text] [PDF]

Home page
 GENES CELLSHome page
S. Ito, K.-i. Takeyama, A. Yamamoto, S. Sawatsubashi, Y. Shirode, A. Kouzmenko, T. Tabata, and S. Kato
In vivo potentiation of human oestrogen receptor {alpha} by Cdk7-mediated phosphorylation
Genes Cells, October 1, 2004; 9(10): 983 - 992.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. del Rio, J. M. G. Pedrero, C. Martinez-Campa, P. Zuazua, P. S. Lazo, and S. Ramos
Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor {alpha} via Calmodulin
J. Biol. Chem., September 10, 2004; 279(37): 38294 - 38302.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A Bardin, N Boulle, G Lazennec, F Vignon, and P Pujol
Loss of ER{beta} expression as a common step in estrogen-dependent tumor progression
Endocr. Relat. Cancer, September 1, 2004; 11(3): 537 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
C. Osipo, H. Liu, K. Meeke, and V. C. Jordan
The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death
Experimental Biology and Medicine, September 1, 2004; 229(8): 722 - 731.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. B. Buck, K. Pfizenmaier, and C. Knabbe
Antiestrogens Induce Growth Inhibition by Sequential Activation of p38 Mitogen-Activated Protein Kinase and Transforming Growth Factor-{beta} Pathways in Human Breast Cancer Cells
Mol. Endocrinol., July 1, 2004; 18(7): 1643 - 1657.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. A. Iannone, C. A. Simmons, S. H. Kadwell, D. L. Svoboda, D. E. Vanderwall, S.-J. Deng, T. G. Consler, J. Shearin, J. G. Gray, and K. H. Pearce
Correlation between in Vitro Peptide Binding Profiles and Cellular Activities for Estrogen Receptor-Modulating Compounds
Mol. Endocrinol., May 1, 2004; 18(5): 1064 - 1081.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. L. Smith and B. W. O'Malley
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Endocr. Rev., February 1, 2004; 25(1): 45 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Tamrazi, K. E. Carlson, and J. A. Katzenellenbogen
Molecular Sensors of Estrogen Receptor Conformations and Dynamics
Mol. Endocrinol., December 1, 2003; 17(12): 2593 - 2602.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Bentrem, J. E. Fox, S. T. Pearce, H. Liu, S. Pappas, D. Kupfer, J. W. Zapf, and V. C. Jordan
Distinct Molecular Conformations of the Estrogen Receptor {alpha} Complex Exploited by Environmental Estrogens
Cancer Res., November 1, 2003; 63(21): 7490 - 7496.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Beliakoff, R. Bagatell, G. Paine-Murrieta, C. W. Taylor, A. E. Lykkesfeldt, and L. Whitesell
Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors
Clin. Cancer Res., October 15, 2003; 9(13): 4961 - 4971.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Sakamoto, Y. Mezaki, H. Shikimi, K. Ukena, and K. Tsutsui
Dendritic Growth and Spine Formation in Response to Estrogen in the Developing Purkinje Cell
Endocrinology, October 1, 2003; 144(10): 4466 - 4477.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. M. Garcia Pedrero, P. Zuazua, C. Martinez-Campa, P. S. Lazo, and S. Ramos
The Naturally Occurring Variant of Estrogen Receptor (ER) ER{Delta}E7 Suppresses Estrogen-Dependent Transcriptional Activation by Both Wild-Type ER{alpha} and ER{beta}
Endocrinology, July 1, 2003; 144(7): 2967 - 2976.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. Kim, N. Thu, B. Saville, and S. Safe
Domains of Estrogen Receptor {alpha} (ER{alpha}) Required for ER{alpha}/Sp1-Mediated Activation of GC-Rich Promoters by Estrogens and Antiestrogens in Breast Cancer Cells
Mol. Endocrinol., May 1, 2003; 17(5): 804 - 817.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. P. Berger, A. E. Petro, K. L. Macnaul, L. J. Kelly, B. B. Zhang, K. Richards, A. Elbrecht, B. A. Johnson, G. Zhou, T. W. Doebber, et al.
Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein {gamma} Selective Modulator
Mol. Endocrinol., April 1, 2003; 17(4): 662 - 676.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. C. Henry and T. A. Gasiewicz
Agonist but Not Antagonist Ligands Induce Conformational Change in the Mouse Aryl Hydrocarbon Receptor as Detected by Partial Proteolysis
Mol. Pharmacol., February 1, 2003; 63(2): 392 - 400.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. N. Miner, C. Tyree, J. Hu, E. Berger, K. Marschke, M. Nakane, M. J. Coghlan, D. Clemm, B. Lane, and J. Rosen
A Nonsteroidal Glucocorticoid Receptor Antagonist
Mol. Endocrinol., January 1, 2003; 17(1): 117 - 127.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. M. Hall and K. S. Korach
Analysis of the Molecular Mechanisms of Human Estrogen Receptors alpha and beta Reveals Differential Specificity in Target Promoter Regulation by Xenoestrogens
J. Biol. Chem., November 8, 2002; 277(46): 44455 - 44461.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. Sathya, M. S. Jansen, S. C. Nagel, C. E. Cook, and D. P. MCDonnell
Identification and Characterization of Novel Estrogen Receptor-{beta}-Sparing Antiprogestins
Endocrinology, August 1, 2002; 143(8): 3071 - 3082.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Levenson, K. M. Svoboda, K. M. Pease, S. A. Kaiser, B. Chen, L. A. Simons, B. D. Jovanovic, P. A. Dyck, and V. C. Jordan
Gene Expression Profiles with Activation of the Estrogen Receptor {alpha}-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor
Cancer Res., August 1, 2002; 62(15): 4419 - 4426.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H.-J. Huang, J. D. Norris, and D. P. McDonnell
Identification of a Negative Regulatory Surface within Estrogen Receptor {alpha} Provides Evidence in Support of a Role for Corepressors in Regulating Cellular Responses to Agonists and Antagonists
Mol. Endocrinol., August 1, 2002; 16(8): 1778 - 1792.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Schulz, M. Eggert, A. Baniahmad, A. Dostert, T. Heinzel, and R. Renkawitz
RU486-induced Glucocorticoid Receptor Agonism Is Controlled by the Receptor N Terminus and by Corepressor Binding
J. Biol. Chem., July 12, 2002; 277(29): 26238 - 26243.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
P. J. Shughrue, G. R. Askew, T. L. Dellovade, and I. Merchenthaler
Estrogen-Binding Sites and Their Functional Capacity in Estrogen Receptor Double Knockout Mouse Brain
Endocrinology, May 1, 2002; 143(5): 1643 - 1650.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Kressler, S. N. Schreiber, D. Knutti, and A. Kralli
The PGC-1-related Protein PERC Is a Selective Coactivator of Estrogen Receptor alpha
J. Biol. Chem., April 12, 2002; 277(16): 13918 - 13925.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
I. T. R. Cavarretta, R. Mukopadhyay, D. M. Lonard, L. M. Cowsert, C. F. Bennett, B. W. O'Malley, and C. L. Smith
Reduction of Coactivator Expression by Antisense Oligodeoxynucleotides Inhibits ER{alpha} Transcriptional Activity and MCF-7 Proliferation
Mol. Endocrinol., February 1, 2002; 16(2): 253 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
D. P. McDonnell, C. E. Connor, A. Wijayaratne, C.-y. Chang, and J. D. Norris
Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators
Recent Prog. Horm. Res., January 1, 2002; 57(1): 295 - 316.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
B. S. KATZENELLENBOGEN, J. SUN, W. R. HARRINGTON, D. M. KRAICHELY, D. GANESSUNKER, and J. A. KATZENELLENBOGEN
Structure-Function Relationships in Estrogen Receptors and the Characterization of Novel Selective Estrogen Receptor Modulators with Unique Pharmacological Profiles
Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 6 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
D. P. McDONNELL, C.-Y. CHANG, and J. D. NORRIS
Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM
Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 16 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
V. C. JORDAN
Chemoprevention with Antiestrogens: The Beginning of the End for Breast Cancer: Daniel G. Miller Lecture
Ann. N.Y. Acad. Sci., December 1, 2001; 952(1): 60 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
R. Metivier, G. Penot, G. Flouriot, and F. Pakdel
Synergism Between ER{alpha} Transactivation Function 1 (AF-1) and AF-2 Mediated by Steroid Receptor Coactivator Protein-1: Requirement for the AF-1 {alpha}-Helical Core and for a Direct Interaction Between the N- and C-Terminal Domains
Mol. Endocrinol., November 1, 2001; 15(11): 1953 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. C. Nagel, J. L. Hagelbarger, and D. P. McDonnell
Development of an ER Action Indicator Mouse for the Study of Estrogens, Selective ER Modulators (SERMs), and Xenobiotics
Endocrinology, November 1, 2001; 142(11): 4721 - 4728.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
S. Nilsson, S. Makela, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, and J.-A. Gustafsson
Mechanisms of Estrogen Action
Physiol Rev, October 1, 2001; 81(4): 1535 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sun, J. E. Paciga, R. I. Feldman, Z.-q. Yuan, D. Coppola, Y. Y. Lu, S. A. Shelley, S. V. Nicosia, and J. Q. Cheng
Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, Activated in Breast Cancer, Regulates and Is Induced by Estrogen Receptor {alpha} (ER{alpha}) via Interaction between ER{alpha} and PI3K
Cancer Res., August 1, 2001; 61(16): 5985 - 5991.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. S. Bramlett, Y. Wu, and T. P. Burris
Ligands Specify Coactivator Nuclear Receptor (NR) Box Affinity for Estrogen Receptor Subtypes
Mol. Endocrinol., June 1, 2001; 15(6): 909 - 922.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
O. M. Conneely
Perspective: Female Steroid Hormone Action
Endocrinology, June 1, 2001; 142(6): 2194 - 2199.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
C. E. Connor, J. D. Norris, G. Broadwater, T. M. Willson, M. M. Gottardis, M. W. Dewhirst, and D. P. McDonnell
Circumventing Tamoxifen Resistance in Breast Cancers Using Antiestrogens That Induce Unique Conformational Changes in the Estrogen Receptor
Cancer Res., April 1, 2001; 61(7): 2917 - 2922.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
W. G. Brake, S. E. Alves, J. C. Dunlop, S. J. Lee, K. Bulloch, P. B. Allen, P. Greengard, and B. S. McEwen
Novel Target Sites for Estrogen Action in the Dorsal Hippocampus: An Examination of Synaptic Proteins
Endocrinology, March 1, 2001; 142(3): 1284 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
W. Feng, P. Webb, P. Nguyen, X. Liu, J. Li, M. Karin, and P. J. Kushner
Potentiation of Estrogen Receptor Activation Function 1 (AF-1) by Src/JNK through a Serine 118-Independent Pathway
Mol. Endocrinol., January 1, 2001; 15(1): 32 - 45.
[Abstract] [Full Text]

Home page
 Physiol. Rev.Home page
J. E. Compston
Sex Steroids and Bone
Physiol Rev, January 1, 2001; 81(1): 419 - 447.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Dutertre and C. L. Smith
Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 431 - 437.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Cell Physiol.Home page
M. E. Nuttall, G. B. Stroup, P. W. Fisher, D. P. Nadeau, M. Gowen, and L. J. Suva
Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells
Am J Physiol Cell Physiol, November 1, 2000; 279(5): C1550 - C1557.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Schafer, E. S. Lee, R. M. O'Regan, K. Yao, and V. C. Jordan
Rapid Development of Tamoxifen-stimulated Mutant p53 Breast Tumors (T47D) in Athymic Mice
Clin. Cancer Res., November 1, 2000; 6(11): 4373 - 4380.
[Abstract] [Full Text] [PDF]